Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + idarubicin + GM-CSF + tioguanine + lomustine + mitoguazone
- Development stage
- Unknown
- Lead developer
- French Innovative Leukemia Organisation
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This multi-drug chemotherapy regimen served as the control arm in the GOELAMS SA4 (French Innovative Leukemia Organisation) Phase 3 clinical trial, which evaluated the addition of fludarabine to standard intensive therapy in elderly patients (ages 60-75) with de novo acute myeloid leukemia (AML). The regimen consists of three distinct phases: an induction phase utilizing cytarabine, idarubicin, and GM-CSF (molgramostim); a consolidation phase with intermediate-dose cytarabine and idarubicin; and a one-year maintenance phase involving 6-thioguanine and cytarabine, interspersed with re-induction courses of lomustine (CCNU), mitoguazone, and cytarabine. The combination targets leukemic cells through multiple mechanisms, including DNA synthesis inhibition, DNA intercalation, and alkylation, while GM-CSF is included to potentially sensitize blasts or accelerate hematologic recovery.
- Other names
- GOELAMS SA4 control regimen
02
Targets
DNAPOLA1 (DNA polymerase alpha)TOP2A (DNA topoisomerase II)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)AMD1 (S-adenosylmethionine decarboxylase)MSH2 (DNA mismatch repair protein MSH2)
Beyond the preview
Go deeper on cytarabine + idarubicin + GM-CSF + tioguanine + lomustine + mitoguazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + idarubicin + GM-CSF + tioguanine + lomustine + mitoguazone.